NME approvals up a tic in 2008

Share this article:
The FDA rang out 2008 with the approval of Ferring's degarelix, for prostate cancer, capping another slow year for new drug approvals.
 
The green light for degarelix followed delays in approvals on Takeda's Actos replacement alogliptin – for which the agency set a new target date of June 2009 – and AstraZeneca's Seroquel XR for major depressive disorder, for which FDA issued a complete response letter (nee “approvable letter”) last week.

An Associated Press analysis of agency approvals, published Dec. 19, counted 21 truly novel drugs approved in 2008 – up from 18 in 2004. The approval of degarelix would push it up to 22. Cold comfort for the many manufacturers that saw potentially pivotal drugs delayed as a cautious agency, still shell-shocked from Vioxx and under withering Congressional scrutiny on drug safety issues, demanded further information.

The AP analysis also said the under-resourced agency missed its target review dates for at least 15 drugs, as it did with alogliptin.

After several years of stagnation, the climate for new drug approvals could improve in 2009, with unified Democratic control of Congress and the White House giving the FDA a freer hand and the prospect of a permanent commissioner steering the often rudderless agency.  
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...